229 related articles for article (PubMed ID: 30792169)
1. Recent trends in treatment of thalassemia.
El-Beshlawy A; El-Ghamrawy M
Blood Cells Mol Dis; 2019 May; 76():53-58. PubMed ID: 30792169
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
3. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.
Motta I; Bou-Fakhredin R; Taher AT; Cappellini MD
Drugs; 2020 Jul; 80(11):1053-1063. PubMed ID: 32557398
[TBL] [Abstract][Full Text] [Related]
4. 2017 Clinical trials update in new treatments of β-thalassemia.
Makis A; Hatzimichael E; Papassotiriou I; Voskaridou E
Am J Hematol; 2016 Nov; 91(11):1135-1145. PubMed ID: 27502996
[TBL] [Abstract][Full Text] [Related]
5. Thalassemia and Nanotheragnostics: Advanced Approaches for Diagnosis and Treatment.
Tariq Z; Qadeer MI; Anjum I; Hano C; Anjum S
Biosensors (Basel); 2023 Apr; 13(4):. PubMed ID: 37185525
[TBL] [Abstract][Full Text] [Related]
6. Emerging Therapies in β-Thalassemia.
Bou-Fakhredin R; Kuo KHM; Taher AT
Hematol Oncol Clin North Am; 2023 Apr; 37(2):449-462. PubMed ID: 36907614
[TBL] [Abstract][Full Text] [Related]
7. Unmet needs in β-thalassemia and the evolving treatment landscape.
Njeim R; Naouss B; Bou-Fakhredin R; Haddad A; Taher A
Transfus Clin Biol; 2024 Feb; 31(1):48-55. PubMed ID: 38128605
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies in β-thalassemia: toward a new era in management.
Bou-Fakhredin R; Tabbikha R; Daadaa H; Taher AT
Expert Opin Emerg Drugs; 2020 Jun; 25(2):113-122. PubMed ID: 32249632
[TBL] [Abstract][Full Text] [Related]
9. Iron overload in thalassemia: different organs at different rates.
Taher AT; Saliba AN
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
[TBL] [Abstract][Full Text] [Related]
10. Beta Thalassemia: Monitoring and New Treatment Approaches.
Khandros E; Kwiatkowski JL
Hematol Oncol Clin North Am; 2019 Jun; 33(3):339-353. PubMed ID: 31030806
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic Mechanisms in Thalassemia II: Iron Overload.
Ganz T; Nemeth E
Hematol Oncol Clin North Am; 2023 Apr; 37(2):353-363. PubMed ID: 36907608
[TBL] [Abstract][Full Text] [Related]
12. Novel Therapeutic Advances in β-Thalassemia.
Makis A; Voskaridou E; Papassotiriou I; Hatzimichael E
Biology (Basel); 2021 Jun; 10(6):. PubMed ID: 34207028
[TBL] [Abstract][Full Text] [Related]
13. Ineffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs.
Longo F; Piolatto A; Ferrero GB; Piga A
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281283
[TBL] [Abstract][Full Text] [Related]
14. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias.
Camaschella C; Nai A
Br J Haematol; 2016 Feb; 172(4):512-23. PubMed ID: 26491866
[TBL] [Abstract][Full Text] [Related]
15. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.
Sleiman J; Tarhini A; Bou-Fakhredin R; Saliba AN; Cappellini MD; Taher AT
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316681
[TBL] [Abstract][Full Text] [Related]
16. An Expert Overview on Therapies in Non-Transfusion-Dependent Thalassemia: Classical to Cutting Edge in Treatment.
Saeidnia M; Fazeli P; Farzi A; Atefy Nezhad M; Shabani-Borujeni M; Erfani M; Tamaddon G; Karimi M
Hemoglobin; 2023 Nov; 47(2):56-70. PubMed ID: 37325871
[TBL] [Abstract][Full Text] [Related]
17. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL; Esrick EB
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
[TBL] [Abstract][Full Text] [Related]
18. Investigational drugs in phase I and phase II clinical trials for thalassemia.
Motta I; Scaramellini N; Cappellini MD
Expert Opin Investig Drugs; 2017 Jul; 26(7):793-802. PubMed ID: 28540737
[TBL] [Abstract][Full Text] [Related]
19. [Research progress of iron metabolism in phenotype modification of β-thalassemia].
Chen D; Sun X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Jan; 38(1):27-31. PubMed ID: 33423253
[TBL] [Abstract][Full Text] [Related]
20. New Insights Into Pathophysiology of β-Thalassemia.
Sanchez-Villalobos M; Blanquer M; Moraleda JM; Salido EJ; Perez-Oliva AB
Front Med (Lausanne); 2022; 9():880752. PubMed ID: 35492364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
